Summary

for people ages 18-85 (full criteria)
at San Francisco, California
study started
estimated completion
Susan Chang

Description

Summary

This is a prospective, Phase 2, single center, open-label study in adult patients with presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of care. In some cases, patients will have had biopsy. Study participants will undergo 68Ga-citrate PET/MR prior to surgery.

Official Title

68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults

Keywords

Glioma Citric Acid Sodium Citrate 68Ga-citrate PET/MR Positive for PTEN deletion Negative for PTEN deletion

Eligibility

You can join if…

Open to people ages 18-85

  • WHO grade 3 or 4 glioma planning to undergo surgery
  • Age >= 18 years
  • Karnofsky performance status of >= 60
  • Ability to understand a written informed consent document, and the willingness to sign it

Cohort A - 20 subjects

  • Positive for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy Cohort B - 20 subjects
  • Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy

You CAN'T join if...

  • Contraindications to PET imaging (e.g. pregnant or breast-feeding woman)
  • Contraindications to MR imaging (e.g. pacemakers, metallic implants, etc.)

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94107 United States

Lead Scientist

  • Susan Chang
    Professor, Neurological Surgery. Authored (or co-authored) 174 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT03335280
Study Type
Observational
Last Updated